Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal SHP611 in children with late infantile metachromatic leukodystrophy
NL-OMON52741Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of cebsulfase alfa in metachromatic leukodystrophy (MLD) (7 arms), sponsored by Takeda. Primary endpoint: Primary efficacy endpoint. Started Sep 2020; status: active, not recruiting.
02
Drugs
cebsulfase alfa
03
Conditions
metachromatic leukodystrophy (MLD)
Beyond the preview
Go deeper on NL-OMON52741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52741.